Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review

Syndax Pharmaceuticals Inc

2025-Q2 EPS reported -$1.82 revenue$57,753,000

Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.
Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.
sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.
Cash, cash equivalents and investments $517.9M; expect funding to profitability.
Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.